Today: 20 March 2026
Subscribe
Browse Category

ASX:RIO.AX 10 January 2026 - 5 March 2026

Rio Tinto plc seals A$1.1 billion Pilbara water deal as Dampier desalination expands

Rio Tinto plc seals A$1.1 billion Pilbara water deal as Dampier desalination expands

Rio Tinto and Western Australia will form a 50:50 joint venture to complete a A$1.1 billion seawater desalination plant near Dampier. The expanded facility will supply 8 gigalitres of water annually to Pilbara towns and industry, with Stage 1 set to deliver water later in 2026. The state will invest A$606 million to double capacity and reduce groundwater extraction from key aquifers.
5 March 2026
··
Fortescue share price rises as FMG investors eye quarterly report and iron ore jitters

Fortescue share price rises as FMG investors eye quarterly report and iron ore jitters

Fortescue shares rose 1.7% to A$22.64, rebounding ahead of its December production report due Thursday. The ASX 200 slipped 0.4%, but materials gained 2.7% on miner strength. Iron ore futures fell after weak China property data, while a fatal blast at a Chinese steel plant raised supply concerns. BHP agreed to lower some iron ore prices in ongoing talks with China Mineral Resources Group.
21 January 2026
···

Stock Market Today

  • Ocugen's Gene Therapy Pipeline Eyes Major 2026-2027 Milestones with Retinal Programs
    March 20, 2026, 9:35 AM EDT. Ocugen (OCGN) is set for a pivotal 2026-2027 with three retinal gene therapy candidates targeting retinitis pigmentosa, Stargardt disease, and geographic atrophy. The lead candidate, OCU400, has completed Phase III enrollment and aims for a rolling biologics license application by Q3 2026 and top-line data in Q1 2027. OCU400 uses a gene-agnostic modifier therapy to treat multiple mutations with one injection. Meanwhile, OCU410ST for Stargardt disease is in a Phase II/III study, with interim data expected in Q3 2026 and FDA filing planned for H1 2027. Both programs fill high unmet medical needs with no approved treatments. Regulatory applications and data readouts heavily influence OCGN's near-term stock catalysts, making timeline execution critical for investors.
Go toTop